A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

NCT ID: NCT06734117

Last Updated: 2025-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5429 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-15

Study Completion Date

2024-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective, non-interventional, single arm, longitudinal cohort multicenter study will recruit approximately 5600 consecutive all-comers, consisting of patients with signs and symptoms of acute coronary syndromes (ACS) who present in the emergency department (ED). The main objective of the study is to determine the clinical performance of Elecsys Troponin T hs Gen 6 versus the centrally adjudicated clinical diagnosis at various time points after ED presentation using the previously determined clinical cut-off of a universal 99th percentile upper reference limit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants With Signs and Symptoms of Acute Coronary Syndromes

The study population will be a consecutive all-comers cohort consisting of patients with signs and symptoms of acute coronary syndromes presenting to the emergency department. Participants will be diagnosed and treated according to the local standard of care at the study site.

Elecsys® Troponin T hs Gen 6

Intervention Type DIAGNOSTIC_TEST

It is an immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in human serum and plasma using cobas e platforms. This investigational immunoassay is intended to aid in the diagnosis of myocardial infarction.

Blood sample collection

Intervention Type PROCEDURE

Blood will be collected from each recruited individual by a healthcare practitioner at five time points after emergency department presentation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Elecsys® Troponin T hs Gen 6

It is an immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in human serum and plasma using cobas e platforms. This investigational immunoassay is intended to aid in the diagnosis of myocardial infarction.

Intervention Type DIAGNOSTIC_TEST

Blood sample collection

Blood will be collected from each recruited individual by a healthcare practitioner at five time points after emergency department presentation.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥20 years
* Signed Informed Consent Form
* Troponin or other cardiac marker determination planned as part of suspected acute coronary syndromes routine care
* Demonstrating symptoms suggestive of acute coronary syndrome and/or myocardial ischemia, such as any of the following:

1. Chest pain, pressure, or a burning sensation across the precordium and epigastrium;
2. Pain that radiates to neck, shoulder, jaw, back, upper abdomen, or either arm;
3. Acute onset or worsening dyspnea;
4. Nausea, vomiting or indigestion;
5. Lightheadedness or syncope;
6. Diaphoresis;
7. Generalized weakness or fatigue; OR, asymptomatic subjects or patients with atypical symptoms in whom myocardial infarction is being suspected.

Exclusion Criteria

* None
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Roche Diagnostics GmbH

INDUSTRY

Sponsor Role collaborator

Roche Diagnostics Operations, Inc.

UNKNOWN

Sponsor Role collaborator

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

El Centro Regional Medical Center

El Centro, California, United States

Site Status

UCSD La Jolla ED

La Jolla, California, United States

Site Status

University of Florida

Gainesville, Florida, United States

Site Status

Tampa General Hospital

Tampa, Florida, United States

Site Status

Parkview Research

Fort Wayne, Indiana, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

Henry Ford Health

Detroit, Michigan, United States

Site Status

Minneapolis Heart Institute Foundation

Minneapolis, Minnesota, United States

Site Status

University at Buffalo / Buffalo General Hospital

Buffalo, New York, United States

Site Status

University of Buffalo - Erie County Medical Center

Buffalo, New York, United States

Site Status

Long Island Jewish Medical Center

New Hyde Park, New York, United States

Site Status

Atrium Health

Charlotte, North Carolina, United States

Site Status

Duke Regional Hospital

Durham, North Carolina, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Atrium Health Wake Forest Baptist, High Point Medical Center

High Point, North Carolina, United States

Site Status

Wake Forest Health Sciences

Winston-Salem, North Carolina, United States

Site Status

Oklahoma Heart Hospital

Oklahoma City, Oklahoma, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

MUSC Health Florence Medical Center

Florence, South Carolina, United States

Site Status

Dallas VA Medical Center

Dallas, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Inova Fairfax Hospital

Falls Church, Virginia, United States

Site Status

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Site Status

Eastside Research Associates

Redmond, Washington, United States

Site Status

MultiCare Institute for Research & Innovation

Tacoma, Washington, United States

Site Status

Aspirus Medical Group

Wausau, Wisconsin, United States

Site Status

Medical University Vienna

Vienna, , Austria

Site Status

MHAT "Heart and Brain"

Burgas, , Bulgaria

Site Status

MHAT "Heart and Brain"

Pleven, , Bulgaria

Site Status

Peking University First Hospital

Beijing, , China

Site Status

Dongguan People's Hospital

Dongguan, , China

Site Status

Sun Yat-sen Memorial Hospital

Guangzhou, , China

Site Status

Shanghai Tongren Hospital

Shanghai, , China

Site Status

TEDA International Cardiovascular Hospital

Tianjin, , China

Site Status

Tongji Hospital

Wuhan, , China

Site Status

Zhongnan Hospital of Wuhan University

Wuhan, , China

Site Status

Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)

Berlin, , Germany

Site Status

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

Universitätsklinikum Heidelberg

Heidelberg, , Germany

Site Status

Tokyo Bay Urayasu Ichikawa Medical Center

Chiba, , Japan

Site Status

Kurashiki Central Hospital

Okayama, , Japan

Site Status

Omihachiman Community Med Center

Ōmihachiman, , Japan

Site Status

Catharina Ziekenhuis

Eindhoven, , Netherlands

Site Status

Akershus University Hospital (AHUS)

Oslo, , Norway

Site Status

Hospital Clinic of Barcelona

Barcelona, , Spain

Site Status

Hospital Alvaro Cunqueiro

Vigo, , Spain

Site Status

University Hospital Basel

Basel, , Switzerland

Site Status

Luzerner Kantonsspital

Lucerne, , Switzerland

Site Status

NHS Lothian

Edinburgh, , United Kingdom

Site Status

Manchester University NHS Foundation Trust

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Bulgaria China Germany Japan Netherlands Norway Spain Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIM RD005477

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.